---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-109016"
form_type: "8-K"
ticker: "APM"
cik: "0001734005"
company_name: "Aptorum Group Ltd"
filed_at: "2026-10-13T20:00:30+00:00"
generated_at: "2026-10-13T20:01:07.543301+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Niki BioSolutions names Thomas Freeburg CFO with $250K salary, 50,000 options at $8.83

## Summary
- Board appointed Thomas Freeburg, 59, as CFO on Oct 9, 2026; two-year term commencing Sept 1, 2026, reporting to CEO Ian Huen.
- Base salary $250,000, with $25,000 deferred until the company raises $3M cumulatively; rises to $275,000 at $5M raised; bonus up to 50% of salary.
- Receives 50,000 stock options at an $8.83 exercise price under the Niki BioSolutions 2026 Equity Incentive Plan; 20 days PTO and $150/month tech allowance.
- Qualifying termination severance: lump sum of remaining base salary through end of Initial Term or six months, whichever is greater, plus COBRA and full unvested equity acceleration.
- Freeburg was CFO/Secretary/Treasurer of Interpace Biosciences (IDXG) from Feb 2021 to Mar 2023, with earlier SEC reporting roles at Tapestry (TPR) and Scholastic (SCHL).

## SEC filing metadata
- accession: 0001213900-26-109016
- form_type: 8-K
- ticker: APM
- cik: 0001734005
- company_name: Aptorum Group Ltd
- filed_at: 2026-10-13T20:00:30+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734005/000121390026109016/0001213900-26-109016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734005/000121390026109016/ea0308307-8k_niki.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-109016
- JSON: https://secwatch.observer/filing/0001213900-26-109016.json
- Plain text: https://secwatch.observer/filing/0001213900-26-109016.txt

## Key facts
- Executive change
  Thomas Freeburg was appointed as Chief Financial Officer at Aptorum Group Ltd.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”), appointed Thomas Freeburg as the Chief Financial Officer, to serve at the discretion of the Board, for a period of two years, commencing as of September 1, 2026, unless terminated sooner by either party.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1734005/000121390026109016/0001213900-26-109016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.